Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

1.

Medial frontal GABA is lower in older schizophrenia: a MEGA-PRESS with macromolecule suppression study.

Rowland LM, Krause BW, Wijtenburg SA, McMahon RP, Chiappelli J, Nugent KL, Nisonger SJ, Korenic SA, Kochunov P, Hong LE.

Mol Psychiatry. 2015 Mar 31. doi: 10.1038/mp.2015.34. [Epub ahead of print]

PMID:
25824298
2.

A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.

Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA.

Schizophr Res. 2015 Feb 24. pii: S0920-9964(15)00071-7. doi: 10.1016/j.schres.2015.01.041. [Epub ahead of print]

PMID:
25728831
3.

Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia.

Chiappelli J, Rowland LM, Wijtenburg SA, Muellerklein F, Tagamets M, McMahon RP, Gaston F, Kochunov P, Hong LE.

Neuropsychopharmacology. 2015 Mar 25. doi: 10.1038/npp.2015.57. [Epub ahead of print]

PMID:
25722115
4.

Risk-taking in schizophrenia and controls with and without cannabis dependence.

Fischer BA, McMahon RP, Kelly DL, Wehring HJ, Meyer WA, Feldman S, Carpenter WT, Gorelick DA.

Schizophr Res. 2015 Feb;161(2-3):471-7. doi: 10.1016/j.schres.2014.11.009. Epub 2014 Nov 22.

PMID:
25467541
5.

Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia.

Wonodi I, McMahon RP, Krishna N, Mitchell BD, Liu J, Glassman M, Hong LE, Gold JM.

Schizophr Res. 2014 Dec;160(1-3):80-7. doi: 10.1016/j.schres.2014.10.026. Epub 2014 Nov 14.

PMID:
25464917
6.

Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.

Buchanan RW, Weiner E, Kelly DL, Gold JM, Keller WR, Waltz JA, McMahon RP, Gorelick DA.

Schizophr Bull. 2014 Nov 2. pii: sbu151. [Epub ahead of print]

PMID:
25368372
7.

Gluten sensitivity and relationship to psychiatric symptoms in people with schizophrenia.

Jackson J, Eaton W, Cascella N, Fasano A, Santora D, Sullivan K, Feldman S, Raley H, McMahon RP, Carpenter WT Jr, Demyanovich H, Kelly DL.

Schizophr Res. 2014 Nov;159(2-3):539-42. doi: 10.1016/j.schres.2014.09.023. Epub 2014 Oct 11.

PMID:
25311778
8.

Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery.

Gray BE, McMahon RP, Green MF, Seidman LJ, Mesholam-Gately RI, Kern RS, Nuechterlein KH, Keefe RS, Gold JM.

Schizophr Res. 2014 Oct;159(1):182-7. doi: 10.1016/j.schres.2014.07.032. Epub 2014 Aug 22.

PMID:
25156338
9.

Multimodal white matter imaging to investigate reduced fractional anisotropy and its age-related decline in schizophrenia.

Kochunov P, Chiappelli J, Wright SN, Rowland LM, Patel B, Wijtenburg SA, Nugent K, McMahon RP, Carpenter WT, Muellerklein F, Sampath H, Hong LE.

Psychiatry Res. 2014 Aug 30;223(2):148-56. doi: 10.1016/j.pscychresns.2014.05.004. Epub 2014 May 21.

PMID:
24909602
10.

Psychological predictors of functional outcome in people with schizophrenia.

Kiwanuka JN, Strauss GP, McMahon RP, Gold JM.

Schizophr Res. 2014 Aug;157(1-3):299-304. doi: 10.1016/j.schres.2014.04.030. Epub 2014 May 27.

PMID:
24878429
11.

Accelerated white matter aging in schizophrenia: role of white matter blood perfusion.

Wright SN, Kochunov P, Chiappelli J, McMahon RP, Muellerklein F, Wijtenburg SA, White MG, Rowland LM, Hong LE.

Neurobiol Aging. 2014 Oct;35(10):2411-8. doi: 10.1016/j.neurobiolaging.2014.02.016. Epub 2014 Feb 28.

PMID:
24680326
12.

Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder.

Koola MM, Gorelick DA, McMahon RP, Liu F, Huestis MA, Linthicum J, Feldman SM, Warren KR, Wehring HJ, Kelly DL.

Schizophr Res. 2014 Jan;152(1):315-6. doi: 10.1016/j.schres.2013.11.035. Epub 2013 Dec 12. No abstract available.

PMID:
24333005
13.

Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia.

Koola MM, Boggs DL, Kelly DL, Liu F, Linthicum JA, Turner HE, McMahon RP, Gorelick DA.

Psychiatry Res. 2013 Oct 30;209(3):273-8. doi: 10.1016/j.psychres.2013.07.044. Epub 2013 Aug 20.

14.

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).

Kelly DL, Wehring HJ, Earl AK, Sullivan KM, Dickerson FB, Feldman S, McMahon RP, Buchanan RW, Warfel D, Keller WR, Fischer BA, Shim JC.

BMC Psychiatry. 2013 Aug 22;13:214. doi: 10.1186/1471-244X-13-214.

15.

Participants with schizophrenia retain the information necessary for informed consent during clinical trials.

Fischer BA, McMahon RP, Meyer WA, Slack DJ, Appelbaum PS, Carpenter WT.

J Clin Psychiatry. 2013 Jun;74(6):622-7. doi: 10.4088/JCP.12m07997.

PMID:
23842013
16.

Comparison of the effectiveness of Conners' CPT and the CPT-identical pairs at distinguishing between smokers and nonsmokers with schizophrenia.

Roth M, Hong LE, McMahon RP, Fuller RL.

Schizophr Res. 2013 Aug;148(1-3):29-33. doi: 10.1016/j.schres.2013.06.012. Epub 2013 Jun 20.

17.

Open-label salsalate for the treatment of pre-diabetes in people with schizophrenia.

Keller WR, Fischer BA, McMahon RP, Meyer W, Buchanan RW.

Schizophr Res. 2013 Jul;147(2-3):408-9. doi: 10.1016/j.schres.2013.04.028. Epub 2013 May 13. No abstract available.

PMID:
23680037
18.

Hypothetical decision making in schizophrenia: the role of expected value computation and "irrational" biases.

Brown JK, Waltz JA, Strauss GP, McMahon RP, Frank MJ, Gold JM.

Psychiatry Res. 2013 Sep 30;209(2):142-9. doi: 10.1016/j.psychres.2013.02.034. Epub 2013 May 9.

19.

General intellectual ability does not explain the general deficit in schizophrenia.

Gray BE, McMahon RP, Gold JM.

Schizophr Res. 2013 Jul;147(2-3):315-9. doi: 10.1016/j.schres.2013.04.016. Epub 2013 May 9.

20.

The relationship between working memory capacity and broad measures of cognitive ability in healthy adults and people with schizophrenia.

Johnson MK, McMahon RP, Robinson BM, Harvey AN, Hahn B, Leonard CJ, Luck SJ, Gold JM.

Neuropsychology. 2013 Mar;27(2):220-9. doi: 10.1037/a0032060.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk